Home » Topics » BioWorld Science

BioWorld Science
RSS

Amgen and Arrakis collaborate to discover and develop targeted RNA degrader therapeutics

Jan. 12, 2022

Leo Pharma discloses IL-17 modulators

Jan. 12, 2022

TuA-derived hPep elicits long-term anticancer immunity in mice

Jan. 12, 2022

Discovery of novel hybrid compounds as antitubercular agents

Jan. 12, 2022

Dysregulation of the tRNA synthetase modulator NOTCH1 behind T-ALL pathogenesis

Jan. 12, 2022

CD22 aberrant splicing confers resistance to therapy in B-ALL

Jan. 12, 2022

Mydecine completes model of new serotonin receptor for AI-driven drug discovery program

Jan. 11, 2022

DiNAQOR and CMRI enter research collaboration on cardiac specific AAV capsids

Jan. 11, 2022

Amarna and Redoxis receive grant to support ALPHAVAC project in neurodegenerative diseases

Jan. 11, 2022

BioNTech and Crescendo Biologics partner to develop immunotherapies for cancer and other diseases

Jan. 11, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...